Molina Healthcare
MOH
$216.04
+7.26%
Molina Healthcare, Inc. is a managed care company providing government-sponsored healthcare plans, primarily through Medicaid, Medicare, and the individual Marketplace exchanges. It operates as a significant player in the Medicaid managed care space, with over 85% of its members coming from state government contracts, particularly in California, New York, Texas, and Washington. The current investor narrative is dominated by the company's recent financial volatility, highlighted by a significant Q4 2025 net loss, which has sparked debate about its near-term profitability and cost management amid broader sector tailwinds from favorable Medicare payment updates.…
MOH
Molina Healthcare
$216.04
Investment Opinion: Should I buy MOH Today?
Rating: Hold. The core thesis is that MOH presents a high-risk, high-potential-reward deep-value situation, but the current fundamental deterioration warrants caution until evidence of a turnaround is clear.
Supporting Evidence: The stock trades at a compelling valuation with a PS ratio of 0.194 and EV/Sales of 0.11, representing a severe discount to historical levels and sector peers. Revenue growth remains robust at 8.34% YoY, and analysts expect a significant earnings rebound to $21.81 EPS, implying a forward P/E of 21.6x. However, these positives are counterbalanced by the severe Q4 net loss of -$160 million, gross margin compression to 6.16%, and negative TTM free cash flow of -$636 million. The technical picture shows a stock that is 31.76% down over the past year but has rebounded 34.24% in three months from deeply oversold levels.
Risks & Conditions: The two biggest risks are 1) the failure to return to positive net income and free cash flow, and 2) further erosion in Medicaid contract margins. This Hold rating would upgrade to a Buy if the company reports a return to profitability (positive net income) in the next quarter and demonstrates quarter-over-quarter gross margin expansion back above 8%. It would downgrade to a Sell if Q4-style losses persist for another quarter or if the stock breaks below the $121 support level on worsening fundamentals. Based on the current data, the stock is fairly valued for its risk profile—the low sales multiple prices in the known problems, but does not yet offer a sufficient margin of safety given the cash burn.
Sign up to view all
MOH 12-Month Price Forecast
The outlook for MOH is bifurcated and highly dependent on the next 1-2 quarters of financial results. The base case (55% probability) of a grinding, volatile recovery is most likely, given the depth of the Q4 issues and the time required for operational fixes. The stock's extreme valuation provides a floor, but the negative cash flow and margin collapse provide a ceiling until proven otherwise. The stance is neutral due to the high uncertainty; the evidence does not yet support a sustained bull case, but the bear case is largely reflected in the price. The stance would upgrade to bullish on confirmation of margin stabilization and positive cash flow in the next earnings report. It would downgrade to bearish if the next quarter shows a continuation or worsening of the Q4 2025 trends.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Molina Healthcare's 12-month outlook, with a consensus price target around $280.85 and implied upside of +30.0% versus the current price.
Average Target
$280.85
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$173 - $281
Analyst target range
Analyst coverage for Molina Healthcare is limited, with only 5 analysts providing estimates, indicating it may be less followed than larger peers, which can contribute to higher volatility. The consensus sentiment appears mixed to cautious, as evidenced by recent institutional rating actions including a downgrade from Wells Fargo to 'Equal Weight' in February and maintained 'Underweight' and 'Hold' ratings from others. The average revenue estimate for the next period is $52.61 billion, and the average EPS estimate is $21.81, implying a significant expected rebound in profitability. However, without a specific consensus price target provided in the data, calculating implied upside is not possible. The wide range in EPS estimates, from a low of $20.53 to a high of $23.52, underscores the uncertainty surrounding the company's earnings recovery path. The pattern of recent ratings—with no outright bullish upgrades and several neutral or cautious stances—suggests analysts are waiting for clearer signs of operational improvement and margin stabilization before turning more positive.
Bulls vs Bears: MOH Investment Factors
The investment thesis for Molina Healthcare is a classic battle between deep value and fundamental deterioration. The bull case is anchored in an extreme valuation discount (PS of 0.19) and the potential for a cyclical recovery in margins, supported by sector tailwinds. The bear case is driven by the severe, recent collapse in profitability and cash flow, which calls into question the sustainability of the business model. Currently, the bear side has stronger near-term evidence, as the Q4 loss and negative cash flows are concrete, recent data points, while the bull case relies on a future recovery that is not yet visible in the financials. The single most important tension is whether the Q4 2025 loss was a one-time operational misstep or the beginning of a structural margin decline. The resolution of this issue—specifically, a return to positive net income and free cash flow in the next quarter—will determine if the stock is a value trap or a deep-value turnaround.
Bullish
- Extreme Valuation Discount: The stock trades at a deeply discounted Price-to-Sales (PS) ratio of 0.194 and EV/Sales of 0.11, which is near the bottom of its historical range and well below typical healthcare plan peers. This pricing reflects severe pessimism, offering significant upside potential if the company can demonstrate a path to margin recovery.
- Strong Revenue Growth Trajectory: Revenue grew 8.34% YoY in Q4 2025 to $11.38 billion, continuing a trend of solid top-line expansion. Analyst consensus expects revenue of $52.61 billion for the next period, indicating sustained growth is anticipated despite profitability issues.
- Sector Tailwinds from CMS Policy: Recent news indicates a larger-than-expected 2027 Medicare Advantage payment increase from CMS, which boosts revenue visibility and sentiment across the managed care sector. As a significant player in government-sponsored plans, MOH is positioned to benefit from this favorable regulatory backdrop.
- Technical Rebound from Oversold Levels: The stock is up 34.24% over the last three months, rebounding sharply from its 52-week low of $121.06. Trading at 41.6% of its 52-week range suggests it was deeply oversold, and the recent momentum indicates a potential bottoming process or bear market rally.
Bearish
- Severe Profitability Collapse in Q4: Q4 2025 saw a dramatic net loss of -$160 million (EPS -$3.15) and gross margin collapsing to 6.16% from 10.6% a year ago. This severe margin compression and negative cash flow of -$298 million in the quarter raise fundamental concerns about cost management and underwriting.
- Persistent Negative Free Cash Flow: Trailing twelve-month free cash flow is -$636 million, indicating the company is burning cash. This raises concerns about its ability to internally fund operations and service its $4.25 billion debt load without relying on external financing, threatening financial flexibility.
- High Dependence on Volatile Medicaid: Over 85% of members come from state Medicaid contracts, concentrated in four states. This creates significant revenue concentration and exposes the company to political and budgetary risks from state governments, which can lead to margin pressure during contract renegotiations.
- Analyst Sentiment Remains Cautious: Analyst coverage is limited (5 analysts) and sentiment is mixed-to-cautious, with recent actions including a Wells Fargo downgrade to 'Equal Weight' and maintained 'Underweight'/'Hold' ratings. The wide EPS estimate range ($20.53 to $23.52) underscores uncertainty about the earnings recovery path.
MOH Technical Analysis
The stock is in a pronounced downtrend from a longer-term perspective, with a 1-year price change of -31.76%, significantly underperforming the SPY's 22.86% gain. Currently trading at $200.28, it sits near the lower end of its 52-week range of $121.06 to $311.52, positioning it at approximately 41.6% of that range, which suggests the stock is deeply oversold and may present a value opportunity, though it also indicates substantial negative momentum and investor skepticism. Recent momentum, however, shows signs of a sharp recovery attempt, with the stock up 34.24% over the last three months and 4.33% over the past month, diverging positively from the severe annual loss. This suggests a potential bottoming process or a bear market rally, but the stock remains highly volatile, as evidenced by the dramatic drop from over $200 in late January to around $122 in mid-February before the recent rebound. Key technical levels are clear, with the 52-week low of $121.06 acting as critical support and the 52-week high of $311.52 representing formidable resistance. A sustained break above the recent recovery highs near $203 could signal a more durable reversal, while a failure and break below the February lows would confirm the primary downtrend's continuation. The stock's beta of 0.799 indicates it is about 20% less volatile than the broader market, which is notable given the managed care sector's typical defensive characteristics, though its recent price action has been anything but stable.
Beta
0.80
0.80x market volatility
Max Drawdown
-61.6%
Largest decline past year
52-Week Range
$121-$312
Price range past year
Annual Return
-26.6%
Cumulative gain past year
| Period | MOH Return | S&P 500 |
|---|---|---|
| 1m | +22.6% | -2.2% |
| 3m | +61.2% | +15.8% |
| 6m | +31.1% | +6.4% |
| 1y | -26.6% | +20.9% |
| ytd | +21.1% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MOH Fundamental Analysis
Revenue growth remains robust but profitability has deteriorated sharply. For Q4 2025, revenue was $11.38 billion, representing an 8.34% year-over-year increase, continuing a trend of solid top-line expansion driven by its core Medicaid segment. However, the most recent quarter revealed severe margin compression, with the company reporting a net loss of -$160 million (EPS of -$3.15) and a gross margin of just 6.16%, a stark decline from the 10.6% gross margin in Q4 2024. This quarterly loss interrupts a pattern of profitability seen in the preceding three quarters of 2025 (Q1 net income: $298M; Q2: $255M; Q3: $79M), indicating significant operational or cost pressures. The company's financial health is under scrutiny due to negative cash flow generation. The trailing twelve-month free cash flow is -$636 million, and the Q4 2025 operating cash flow was -$298 million. While the balance sheet shows moderate leverage with a debt-to-equity ratio of 0.97 and a healthy current ratio of 1.69, the persistent negative cash flow raises concerns about the company's ability to internally fund operations and service its debt without relying on external financing or its cash reserves, which stood at $4.25 billion at the end of Q4.
Quarterly Revenue
$11.4B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.06%
Latest Quarter
Free Cash Flow
$-636000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MOH Overvalued?
Given the company reported a net loss in the most recent quarter, the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. Molina trades at a trailing PS ratio of 0.194 and an EV/Sales of 0.11, which are extremely low multiples. The forward PE ratio of 21.6x, based on estimated EPS, suggests the market is pricing in a return to profitability, but the negative trailing PE of -13.8x reflects the recent quarterly loss. Compared to typical healthcare plan providers, these sales multiples represent a significant discount, likely reflecting the market's punitive assessment of the recent profitability collapse and cash flow challenges. Historically, Molina's valuation has compressed dramatically from its recent peaks; for instance, its PS ratio was above 0.77 in late 2025 and has since fallen to the current 0.19 level. Trading near the bottom of its own historical valuation range suggests the stock is pricing in substantial pessimism, potentially offering a deep value opportunity if the company can stabilize its margins, but also signaling perceived fundamental deterioration that may not be fully resolved.
PE
19.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -14x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The company faces acute financial risk from its deteriorating profitability and negative cash flow generation. The Q4 2025 net loss of -$160 million and gross margin collapse to 6.16% from 10.6% YoY indicate severe operational pressures, likely from medical cost trends or pricing missteps. With a trailing FCF of -$636 million, MOH is burning cash, which threatens its ability to service its debt (D/E of 0.97) without tapping its $4.25 billion cash reserves or external markets. This cash burn rate, if sustained, could force dilutive financing or a dividend cut, though it currently pays none.
Market & Competitive Risks: The primary market risk is valuation compression, as the stock has already experienced a -62.57% max drawdown and trades at a fraction of its recent highs. Despite its low PS ratio, a failure to demonstrate margin recovery could lead to further multiple contraction. Competitively, MOH's heavy reliance on Medicaid (over 85% of members) creates concentration risk, as state budget pressures or contract losses in key states like California or Texas could materially impact revenue. The stock's beta of 0.799 suggests it is less volatile than the market, but its recent price action has been highly unstable, indicating idiosyncratic risk dominates.
Worst-Case Scenario: The worst-case scenario involves a continuation of the Q4 2025 cost trends, leading to consecutive quarterly losses, a credit rating downgrade due to persistent negative cash flow, and the loss of a major state Medicaid contract. This could trigger a liquidity crisis, forcing asset sales or equity dilution. In this adverse scenario, the stock could re-test and break below its recent 52-week low of $121.06. From the current price of $200.28, this represents a potential downside of approximately -40%. A breach of this support could see a fall towards the $100 level, reflecting a total enterprise value discount if the business model is perceived as broken.
FAQ
The key risks are, in order of severity: 1) Financial/Operational Risk: Continued negative free cash flow (-$636M TTM) and margin pressure, as seen in the Q4 gross margin drop to 6.16%. This could lead to a liquidity crunch. 2) Business Model Risk: Over 85% revenue concentration in state Medicaid contracts, making the company vulnerable to government funding changes and intense pricing pressure. 3) Execution Risk: Failure to return to profitability could trigger a further de-rating, with the stock potentially re-testing its 52-week low of $121.06 (-40% downside). 4) Market Sentiment Risk: Limited analyst coverage (5 analysts) and cautious ratings increase volatility and reduce visibility during the recovery process.
The 12-month forecast is highly binary, centered on the company's ability to fix its margins. The base case (55% probability) sees a volatile recovery with a target range of $185-$230, driven by modest earnings improvement. The bull case (25% probability) envisions a successful turnaround, with margins recovering and the stock re-rating towards its 52-week high, targeting $260-$311. The bear case (20% probability) involves further operational deterioration, pushing the stock back to its 52-week low range of $121-$160. The most likely scenario is the base case, as it assumes the Q4 issues are addressable but will take time to resolve, leading to choppy trading rather than a V-shaped recovery.
Based on sales multiples, MOH appears deeply undervalued. Its Price-to-Sales ratio of 0.194 and EV/Sales of 0.11 are at the extreme low end of its historical range and well below typical managed care peers. This discount reflects the market's punitive assessment of its recent profitability collapse. On a forward earnings basis, the P/E of 21.6x (based on estimated EPS of $21.81) is reasonable if the earnings recovery materializes. The valuation implies the market expects either a prolonged period of depressed margins or further deterioration. Therefore, the stock is statistically cheap but fundamentally challenged—it is fairly valued for its current risk profile but would be undervalued if operations stabilize.
MOH is a speculative buy only for investors with a high risk tolerance and a value/contrarian mindset. At a current PS ratio of 0.19, it is priced for disaster, offering significant upside potential of 30-55% if it executes a turnaround (analyst EPS implies a forward P/E of 21.6x). However, the recent Q4 2025 net loss of -$160 million and negative free cash flow pose substantial fundamental risks. It is not a good buy for conservative or income-seeking investors. A potential buyer should be prepared for high volatility and should only invest if they believe the company's margin collapse is a temporary, fixable issue.
MOH is unsuitable for short-term trading due to its high volatility and fundamental uncertainty. The recent 34% 3-month rebound suggests a potential bottom, but the path is unlikely to be smooth. Given the deep-value, turnaround nature of the thesis, it is more appropriate for a long-term (2-3 year) investment horizon, allowing time for management to execute operational fixes and for the valuation discount to potentially close. The stock pays no dividend (yield 0%) and its beta of 0.799 suggests it is less correlated to the market, but its recent price action has been driven by company-specific news. Investors should be prepared to hold through significant volatility while monitoring quarterly execution.